Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium

Epidemiology and Infection

Volumn 139, Issue 4, 2011, Pages 494-504

  Theeten, H ^a   Hutse, V ^b   Hens, N ^a,c   Yavuz, Y ^c   Hoppenbrouwers, K ^d   Beutels, P ^a   Vranckx, R ^b   Van Damme, P ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c HASSELT UNIVERSITY   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Diphtheria; measles (rubeola); mumps; rubella; tetanus

Indexed keywords

DIPHTHERIA TETANUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; BACTERIUM ANTIBODY; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGE; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BELGIUM; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DIPHTHERIA; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFANT; INFECTION CONTROL; INFECTION RISK; MEASLES; MEASLES VACCINATION; MUMPS; PRESCHOOL CHILD; PUBLIC HEALTH PROBLEM; PUBLIC HEALTH SERVICE; RUBELLA; SCHOOL CHILD; SERODIAGNOSIS; SEROPREVALENCE; TETANUS; TETANUS PROPHYLAXIS; BLOOD; EPIDEMIOLOGY; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; BELGIUM; CHILD; CHILD, PRESCHOOL; DIPHTHERIA; DIPHTHERIA-TETANUS VACCINE; FEMALE; HUMANS; INFANT; MALE; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MIDDLE AGED; MUMPS; RUBELLA; SEROEPIDEMIOLOGIC STUDIES; TETANUS; YOUNG ADULT;

EID: 79955699900     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268810001536     Document Type: Article

References (43)

1. Osborne K, et al. Ten years of serological surveillance in England and Wales: methods, results, implications and action. International Journal of Epidemiology 2000; 29: 362-368.
2. Osborne K, Weinburg J, Miller E. The European Seroepidemiology Network. Eurosurveillance 1997; 2: 29-31.
3. Gabutti G, et al. The epidemiology of mumps in Italy. Vaccine 2008; 26: 2906-2911.
4. de Melker HE, Conyn-van Spaendonck MA. Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiology and Infection 1998; 121: 637-643. (Pubitemid 29023043)
5. Vandermeulen C, et al. Vaccination coverage in 14-yearold adolescents : Documentation, timeliness, and sociodemographic determinants. Pediatrics 2008; 121: E428-E434.
6. Swennen B, et al. Analysis of factors influencing vaccine uptake: perspectives from Belgium. Vaccine 2001; 20: S5-S7. (Pubitemid 32924998)
7. Theeten H, et al. Coverage of recommended vaccines in children at 7-8 years of age in Flanders, Belgium. Acta Paediatrica 2009; 98: 1307-1312.
8. Swennen B, Robert E. Vaccination coverage survey in infants at 18-24 months of age in the French region (excluding Brussels). Brussels, Belgium: PROVACUniversité Libre de Bruxelles ; November 2009.
9. Theeten H, et al. Infant vaccination coverage in 2005 and predictive factors for complete or valid vaccination in Flanders, Belgium: an EPI-survey. Vaccine 2007; 25: 4940-4948. (Pubitemid 46843432)
10. Mathei C, et al. Diphtheria immunity in Flanders. European Journal of Clinical Microbiology & Infectious Diseases 1997; 16: 631-636. (Pubitemid 27470335)
11. Andrews N, et al. Towards elimination : measles susceptibility in Australia and 17 European countries. Bulletin of the World Health Organization 2008; 86: 197-204. (Pubitemid 351480939)
12. Nardone A, et al. Comparison of rubella seroepidemiology in 17 countries : progress towards international disease control targets. Bulletin of the World Health Organization 2008; 86: 118-125. (Pubitemid 351222526)
13. Edmunds WJ, et al. The sero-epidemiology of diphtheria in Western Europe. ESEN Project. European Sero-Epidemiology Network. Epidemiology and Infection 2000; 125: 113-125.
14. Anon. Diphtheria vaccine. WHO Weekly Epidemiological Record 2006; 3: 24-32.
15. Anon. Tetanus vaccine. WHO Weekly Epidemiological Record 2006; 20: 198-208.
16. Gergen PJ, et al. A population-based serologic survey of immunity to tetanus in the United States. New England Journal of Medicine 1995; 332: 761-766.
17. Skendzel LP. Rubella immunity. Defining the level of protective antibody. American Journal of Clinical Pathology 1996; 106: 170-174. (Pubitemid 26277203)
18. Anon. Total and Belgian population at 1 January 2006. Brussels : FPS Economy, General Directorate Statistics and Economic Information, 2009. Report No. S220.A1N/2006.
19. WHO. Eliminating measles and rubella and preventing congenital rubella infection : WHO European Region strategic plan 2005-2010. Copenhagen, Denmark: WHO Regional Office for Europe; 2006. Report No.: ISBN 92 890 1382 6.
20. Boonen M, et al. Vaccination coverage in infants and adolescents in Flanders. Vlaams Infectieziektenbulletin 2009; 68: 9-14.
21. Vander Veken J, Van Casteren V. Surveillance of measles and mumps by sentinel family physicians in Belgium, 1982-1993. Brussels : Institute of Public Health, 1994. Report No.: D/1994/2505/29.
22. Beutels P, et al. The difficult quest for data on 'vanishing' vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium). Vaccine 2002; 20: 3551-3559. (Pubitemid 35248080)
23. Amela C, Pachon I, de Ory F. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey. European Journal of Epidemiology 2002; 18: 71-79. (Pubitemid 36401838)
24. Mossong J, Putz L, Schneider F. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study. Epidemiology and Infection 2004; 132: 11-18. (Pubitemid 38240067)
25. Tischer A, Gerike E. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. Vaccine 2000; 18: 1382-1392. (Pubitemid 30017851)
26. Lernout T, et al. An outbreak of measles in orthodox Jewish communities in Antwerp, Belgium, 2007-2008: different reasons for accumulation of susceptibles. Eurosurveillance 2009; 14: 15-18.
27. Chen RT, et al. Measles antibody - reevaluation of protective titers. Journal of Infectious Diseases 1990; 162: 1036-1042. (Pubitemid 20353580)
28. Ratnam S, et al. Comparison of commercial enzyme-immunoassay kits with plaque reduction neutralization test for detection of measles-virus antibody. Journal of Clinical Microbiology 1995; 33: 811-815.
29. Samb B, et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatric Infectious Disease Journal 1995; 14: 203-209.
30. Vandermeulen C, et al. Outbreak of mumps in a vaccinated child population: a question of vaccine failure ? Vaccine 2004; 22: 2713-2716. (Pubitemid 38900645)
31. Briss PA, et al. Sustained transmission of mumps in a highly vaccinated population - assessment of primary vaccine failure and waning vaccine-induced immunity. Journal of Infectious Diseases 1994; 169: 77-82.
32. Sabbe M, Hue D. Surveillance of infectious diseases in children in Belgium. Pedisurv, annual report 2008. 2009. Report No.: IPH/EPIREPORTS no. 2008-052.
33. Plotkin SA, Reef S. Rubella vaccine. In: Plotkin SA, Orenstein WA, Offit P, eds. Vaccines, 5th edn. Philadelphia : Saunders, Elsevier, 2008, pp. 735-771.
34. Vyse AJ, et al. Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century. Epidemiology and Infection 2006; 134: 1303-1312. (Pubitemid 44614954)
35. Vandermeulen C. 25 years of measles-mumps-rubella vaccination. Epidemiological and immunological considerations regarding mumps (dissertation). Leuven, Belgium: Katholieke Universiteit Leuven, 2009, pp. 1-164.
36. Kafatos G, Andrews N, Nardone A. Model selection methodology for inter-laboratory standardisation of antibody titres. Vaccine 2005; 23: 5022-5027. (Pubitemid 41267030)
37. Tischer A, et al. Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia. Epidemiology and Infection 2007; 135: 787-797.
38. Thomas C, Moridani M. Interindividual variations in the efficacy and toxicity of vaccines. Toxicology (in press).
39. Anderson R, May R. Immunisation and herd immunity. Lancet 1999; 335: 641-645.
40. Stubbe M, et al. Seroprotection against tetanus in patients attending an emergency department in Belgium and evaluation of a bedside immunotest. European Journal of Emergency Medicine 2007; 14: 14-24. (Pubitemid 46052135)
41. Olander RM, et al. High tetanus and diphtheria antitoxin concentrations in Finnish adults - time for new booster recommendations? Vaccine 2009; 27: 5295-5298.
42. Kelly H, et al. A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine 2002; 20: 3130-3136.
43. Rota MC, et al. Measles serological survey in the Italian population: interpretation of results using mixture model. Vaccine 2008; 26: 4403-4409.